Skip to main content

Table 3 Relationships between clinicopathological criteria, cytoplasmic IGFBP-3 and patient outcome

From: Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome

Variable

Univariate analysis

Multivariate analysis

 

95% CI

P

95% CI

P

Overall survival

    

   Age

0.99–1.04

0.4

0.98–2.90

0.009

   Lymph node status (+/-)

2.79–153.9

0.004

2.65–161

0.003

   Invasive tumour grade (I, II, III)

1.27–4.93

0.002

1.14–4.62

0.002

   Tumour size

1.02–1.05

<0.001

1.02–1.05

<0.001

   NPI

1.48–3.36

<0.001

1.39–3.32

<0.001

   ER (quick-score)

0.66–0.92

0.002

0.68–0.98

0.03

   HER-2 IHC score

0.94–2.02

0.04

0.76–1.95

0.56

   Ki67 proliferative index

0.99–1.00

0.4

0.99–1.00

0.65

   Lymphovascular invasion (+/-)

1.46–9.38

0.006

0.89–6.69

0.08

   IGFBP-3 IHC score

0.62–2.01

0.719

0.59–2.50

0.592

Disease-free survival

    

   Age

0.97–1.02

0.9

0.99–1.06

0.06

   Lymph node status (+/-)

2.29–25.3

<0.001

2.06–25.6

0.002

   Invasive tumour grade (I, II, III)

1.48–5.38

0.005

1.36–5.11

0.006

   Tumour size

1.02–1.04

<0.001

1.02–1.04

<0.001

   NPI

1.46–3.17

<0.001

1.38–3.15

<0.001

   ER (quick-score)

0.66–0.89

0.001

0.68–0.95

0.01

   HER-2 IHC score

1.04–1.92

0.02

0.95–1.87

0.2

   Ki67 proliferative index

0.99–1.00

0.2

0.99–1.00

0.3

   Lymphovascular invasion (+/-)

1.63–6.95

0.002

1.09–6.65

0.03

   IGFBP-3 IHC score

0.61–1.71

0.922

0.57–1.90

0.896

  1. Confidence intervals (CI) and P values are given for the results of both the univariate and multivariate analyses. The multivariate analysis is adjusted for Nottingham Prognostic Index (NPI) (nodes, grade and size) and treatment (tamoxifen/chemotherapy/none). Data for univariate analysis were evaluable in 95 patients (reflecting the exclusion of six local tumour recurrences as described in the Methods section) and included a multivariate analysis on 84 cases that excluded non-evaluable NPI in 11 patients. All clinicopathological variables and cytoplasmic IGFBP-3 immunohistochemistry (IHC) scores were analysed as a continuum, with lymph node status and lymphovascular invasion assessed as present or absent. Significant P values (P < 0.05) are indicated in bold.
  2. ER, oestrogen receptor.